Nexstim Plc completes negotiations under the co-operation within undertakings act
Company announcement, insider information, Helsinki, 26 March 2020, at 7.00 pm (EET)
Nexstim Plc completes negotiations under the co-operation within undertakings act
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), announces that it has completed the co-operation negotiations.
On 18 March 2020 the Company announced that it will initiate co-operation negotiations concerning all personnel in Finland, as a part of Nexstim Group cost savings plan aiming to reach up to EUR 3 million annual savings from its global operations.
The co-operation negotiations in Finland have now ended and as a result, the Company decided to temporarily lay off all its personnel for maximum of 90 days. The lay offs may be executed as full time or part time lay offs. There were no terminations of employment in Finland. The cost savings plan led to termination of employment of total of six persons in the Company’s foreign subsidiaries.
The Company estimates that with these cost saving measures, it will reach savings of approximately EUR 0.8 million during the next three months, with which when annualized, the Company will reach its target of up to EUR 3 million annual savings.
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, toimitusjohtaja
+358 50 326 4101
Sisu Partners Oy (Certified Adviser)
+ 358 40 842 4479
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.
For more information please visit www.nexstim.com
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
PRESS RELEASE: NACON: TOYOTA GAZOO RACING BECOMES ESPORTS WRC PRESENTING SPONSOR2.6.2020 07:45:10 CEST | Press release
TOYOTA GAZOO RACING BECOMES ESPORTS WRC PRESENTING SPONSOR OFFERING TOYOTA GR YARIS TO THE WINNER Lesquin, June 2nd, 2020 – NACON and its development studio KT Racing, in collaboration with WRC Promoter, are pleased to announce that TOYOTA GAZOO Racing will become the presenting sponsor of the 2020 and 2021 eSports WRC seasons. The announcement celebrates the Japanese manufacturer’s recent unveiling of the all-new Toyota GR Yaris, a pure performance car born from Toyota’s title-winning experience in the World Rally Championship. Equipped with Toyota’s new GR-FOUR intelligent all-wheel drive system and a thrilling 1.6-litre 3-cylinder turbocharged engine delivering 261 DIN hp and 360 Nm of torque, the all-new Toyota GR Yaris promises to be lightweight, powerful and exhilarating – a fitting prize for the eSports WRC Champion! The partnership between TOYOTA GAZOO Racing and NACON will extend into further promotions spanning WRC 8 as well as WRC 9, the latest instalment of the official WRC
EXEL INDUSTRIES :2019-2020 First-Half Results The initial benefits of our reorganization blacked out by the impact of the health crisis and depreciation of goodwill 1st semester 20191st semester 20202.6.2020 07:00:00 CEST | Press release
PRESS RELEASE Paris, June 2, 2020 2019-2020 First-Half Results The initial benefits of our reorganization blacked out by the impact of the health crisis and depreciation of goodwill 1st semester 20191st semester 2020in M€Oct 18 - Mar 19Oct 19 - Mar 20Revenue348.9314.3Current Operating Income5.0-1.1%1.4%-0.3%Non-recurring items-4.2-28.9Financial expenses-1.9-1.8(Losses)/gains on foreign exchange2.9-4.4Profit before tax1.7-36.2Tax expense-0.7-0.4Share of profit of associates0.20.2Net income 1.2-36.4 ·Analysis of 2019-2020 first-half results The decline in current operating income over the first-half of 2019-2020 was due primarily to the drop in revenue from Agricultural and Industrial Spraying due to the global health crisis. The reorganization initiated in 2019 produced visible results for the Sugar Beet Harvesting business. With respect to Agricultural Spraying, we expect an improvement by the end of the financial year. The very uncertain macro-economic context, notably as a result of
Mitsubishi Corporation and NTT complete acquisition of 30% stake in HERE Technologies2.6.2020 07:00:00 CEST | Press release
June 2, 2020 Amsterdam and Tokyo – HERE Technologies today announced that Mitsubishi Corporation (MC) and Nippon Telegraph and Telephone Corporation (NTT) of Japan have completed their joint acquisition of a 30% ownership stake in the company, after receiving regulatory approvals. HERE welcomes MC and NTT as strategic investors. The two companies have co-invested in HERE via their recently established, jointly owned holding company COCO Tech Holding B.V. in the Netherlands. As a result, HERE now has nine direct and indirect shareholders: Audi, Bosch, BMW Group, Continental, Intel Capital, MC, Mercedes-Benz, NTT and Pioneer. Following the transaction, HERE has added two new members to its Supervisory Board: Mr. Yutaka Kyoya, Executive Vice President, Group CEO, Consumer Industry Group, Mitsubishi Corporation; and Mr. Hiroki Kuriyama, Member of the Board, Executive Vice President, Head of Strategic Business Development, NTT. HERE’s broadened shareholder structure supports the company’s
Prosafe SE: Update on financial situation and process with lenders2.6.2020 07:00:00 CEST | Press release
Prosafe refers to the information on its financial status and process with lenders that has been provided over time and lastly in the Q1 2020 report published on 26 May 2020. The company has gained support to an extension to the previously reported forbearance arrangement with a majority of its lenders across its USD 1,300 million and USD 288 million facilities from end May 2020 till end June 2020. As part of this, the company will continue to defer making payments of scheduled instalments and interests under both facilities. Similarly, payment of the final instalment owed and due under the seller credit to Cosco for the Safe Notos remains as initially reported on 13 February subject to ongoing discussions with Cosco and the lenders. The company's discussions with its lenders remain constructive. The forbearance arrangement shows support for the company and creates stability to work with lenders to agree a long term financial solution, while lenders reserve their rights. Pending this,
FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer2.6.2020 07:00:00 CEST | Press release
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma Tecentriq combination improved overall survival and progression-free survival compared to the previous standard of careApplication approved under FDA’s Project Orbis initiative and Real-Time Oncology Review pilot programme Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph.D., Chief Medi
EVS Broadcast Equipment reports update of share buyback program2.6.2020 06:45:00 CEST | Press release
Publication on June 2, 2020, before market opening Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on May 6, 2020, took place between May 25, 2020 and May 29, 2020. DateNumber of shares acquiredAverage price (EUR)Total (EUR)25/05/20202,500 13.7820 34,45526/05/20202,500 13.9834 34,95927/05/20202,500 14.2910 35,72828/05/20202,500 14.8076 37,01929/05/20202,500 14.4971 36,243Total12,50014.2722 178,403 As of May 29, 2020, and since the start of the buyback program, EVS has bought 27,267 shares at an average price of EUR 14,0123, representing in total EUR 382,072. After aforementioned transactions the total number of own shares amounts now to 618,319 shares as of May 29, 2020 (including 607,332 shares already held by the